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Abstract
Recently, various nanomaterials are used in order to develop nanotechnology‐based
rapid  diagnostic  tests,  such  as  metallic  nanoparticles,  quantum  dots  (QDs),  silica
nanospheres,  magnetic  nanoparticles,  carbon  nanotubes  (CNTs),  silicon  nanowires
(SiNWs), nanopores, graphene, nanostructured surfaces, and metal films. This novel
nanodiagnostic  approach will  further  develop point‐of‐care (POC) diagnostics  and
monitoring technologies.  Nanobiosensors and microarrays of biosensors can create
biochip systems and microfluidic platforms that are the most used nanofabrications for
rapid diagnostic tests. These nanoplatforms are constructed for the rapid detection of
various diseases or pathogen‐specific biomolecules/markers, such as DNA, proteins,
whole cells (e.g., circulating tumor cells), and others. The fabrication of small‐scale
portable devices with the incorporation of nanostructures will offer many advantages
in the early detection of various diseases and health‐threatening infections by pathogens
and in the treatment selection and treatment monitoring. The use of nanostructures in
in vitro  diagnostics gives the opportunity to augment the sensitivity and specificity
required in clinical practice, lowers the cost and test time of the assays, and enables
portable  microfluidic  platforms  suitable  for  resource‐constrained  settings.  In  this
chapter, all the state‐of‐the‐art advantages in this field are discussed, starting with the
nanostructures used for the fabrication of nanobiosensors, nanobiosensors arrays, and
nanofluidic platforms and the nanodiagnostic use of rapid tests in the detection of
pathogens, in cancer management, and glucose monitoring for the management of
diabetes disease.
Keywords: Nanotechnology, Nanostructures, point‐of‐care devices, nanodiagnostics,
low‐cost and rapid diagnosis
1. Introduction
Nanostructures are used in order to create specific nanodevices for the manipulation of biological
systems at the molecular level, and this is what currently defines nanomedicine. So far, the
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integration of nanoparticles with biology has led to the development of diagnostic devices,
contrast  agents,  advanced therapy applications,  drug delivery therapy,  and imaging ap‐
proaches. Nanomedicine offers many advantages in everyday clinical practice, taking into
consideration the non‐invasive approach of the samples used, fast reaction times, specificity,
and sensitivity that nanoparticles can offer. Therein, these advantages will lead us closer to the
construction of point‐of‐care mobile nanodevices. In the context of in vitro nanodiagnostics,
nanotechnology allows the construction of novel sensors and in vitro tests, in order to im‐
prove the sensitivity of existing tests, to develop new diagnostic test platforms, and to allow
point‐of‐care applications. Thus, Nanodiagnostics is defined as the application of nanotechnol‐
ogy for the diagnosis of a dysfunction and/or disease in human, at the earliest stage possible,
ideally at the level of a single cell. To achieve this goal, various types of nanotechnologies are
currently being explored for use in nanodiagnostic applications. Furthermore, an increase in
knowledge  in  basic  research  will  be  seen  through the  development  of  microscopic  and
spectroscopic  techniques  towards  ultrahigh  spatial  resolution,  molecular  resolution,  and
ultrahigh sensitivity that will also help in the creation of advanced in situ diagnostics tools. More
specifically, nanotechnology‐based diagnosis techniques offer great opportunities such as
1. Rapid diagnostic test, potentially in the doctor's office or bedside tests, for the initial
diagnosis and treatment selection and treatment monitoring to the doctor/hospital or even
at home.
2. The early detection of  several  diseases in comparison with the efficiency of  current
techniques. The early detection is very important as it offers the opportunity for earlier
diagnosis and thus more therapeutic opportunities.
This chapter summarizes the nanostructures used in nanodiagnostic tests and their applica‐
tions for the development of rapid diagnostic tests for point‐of‐care disease management and
public health.
2. Nanostructures used in nanodiagnostics
The term nanostructures includes materials of <100 nm in size in at least one dimension. There
are nanostructures in zero‐dimensional (0D), one‐dimensional, (1D), and two‐dimensional
(2D) systems. The dimensions of nanostructures are advantageous for use in diagnostics
because they are in the range of the size of various biomolecules such as nucleic acids, small
proteins, and viruses. An in vitro diagnostic tool is always comprised of an element that is able
to identify a biochemical change, activity or concentration of a specific molecule of biologi‐
cal importance in the solution of interest. In a nanobiosensor, a transducer is used to convert
this biochemical signal into a quantifiable signal.
The use of nanomaterials in the design of in vitro diagnostic systems is offering types of sensors
that are characterized by specificity, sensitivity, and robustness. Several kinds of nanomateri‐
als have found attractive applications in in vitro diagnostic tests, such as metallic nanoparti‐
cles, quantum dots (QDs), silica nanospheres, magnetic nanoparticles, which belong to the
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zero‐dimensional (0D) systems, carbon nanotubes (CNTs), silicon nanowires (SiNWs),
nanopores, which belong to the one‐dimensional (1D) systems, and graphene, nanostruc‐
tured surfaces, and metal films, which belong to the two‐dimensional (2D) systems.
2.1. Metallic NPs
Metals, especially gold and silver, have the advantageous ability to interact with external fields
such as light, radiofrequency, and X‐rays. Under a specific wavelength, metals exhibit surface
plasmon resonance (SPR), the oscillation of free electrons in a particle's surface; thus, they can
successfully be combined with conventional methods such as colorimetry or absorption
spectroscopy. A typical example of SPR biosensing consists of the liquid sample part and an
immobilized ligand (e.g., an antibody) on an SPR‐active gold‐coated glass slide. This system
can create a thin flow cell in which the sample will be able to flow in the aqueous solution, and
when light (visible or near infrared) is projected through the glass slide and onto the gold
surface at angles and wavelengths near the SPR condition, the optical reflectivity of the gold
changes in a specific way when an actual interaction occurs between the sample and the ligand
of the solid phase. The most frequent medical use of these NPs is the rapid tests, for example,
pregnancy test kits, where gold nanoparticles are used as a color marker [1]. Moreover, metallic
NPs are suitable for surface‐enhanced Raman spectroscopy (SERS), since they produce Raman
signal. So, when molecules are in close proximity to a metal surface, they exhibit a dramatic
augmentation in the electromagnetic field, yielding high Raman intensity. Thus, SERS surface
biosensors are usually performed on Ag, Au, or Cu surfaces. SERS is an excellent assay for the
sensitive and specific detection of low‐concentration molecules, for example, the detection of
biomarkers for bacillus spores or the measurement of glucose after the appropriate chemical
modifications of the SERS surfaces [2]. Another example is the molecular sentinels, which are
comprised of metal NPs decorated with a Raman label‐conjugated stem‐loop DNA. Thus,
when the DNA molecule is in close proximity to the metal surface, the Raman intensity is
maintained high. In contrast, in the bound state, there is a disruption of the stem‐loop and the
Raman label is no longer in close proximity to the metal. This approach was used to detect the
gag gene of the HIV‐1 in PCR amplicons [3] and several single‐nucleotide polymorphisms
(SNPs) such as BRCA1 gene of breast cancer, using plasmonic nanoprobes that detach from
the Raman tag when the conjugated oligonucleotide is hybridized, thus decreasing the
plasmonic effect and change the SERS [4].
2.2. Quantum dots (QDs)
In the field of in vitro applications, nanoparticles are mainly used as markers for biomole‐
cules, since they have many optical advantages that make them suitable for several diagnos‐
tic assays such as PCR, for the construction of biochips or suitable for multiplexing, conversely
to the traditional dyes used in every day clinical practice. To this end, inorganic fluorescent
nanoparticles are being investigated such as semiconductor nanoparticles (quantum dots) or
nanoparticles‐like nanophopsphors, resulting in an increase in sensitivity and specificity and
the possible analysis of multiple analytes that offer opportunities of mass production [5].
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Quantum dots, semiconductor nanocrystals coated with inorganic materials, are also current‐
ly used in the field of basic research of cell biology, and their use in clinical diagnostic tests is
already under investigation with great progress as markers, especially in image‐guided
techniques, and at the same time, some nanobiochip platforms are already in the market. More
importantly, QDs are very efficient donors of energy compared to traditional organic dyes,
especially dye acceptors in FRET‐based assays (fluorescence resonance energy transfer) [6].
2.3. Silica nanospheres
Just like QDs, inorganic dye‐loaded silica particles are characterized by good photostability,
sharp emission peaks, and long‐lasting fluorescence lifetimes. They are appropriate for
dispersion aqueous solutions, due to their hydrophilic surface. They are usually used to
conjugate optical labels in order to increase the detection signal, such as organic or inorganic
dye molecules (lanthanide‐based and ruthenium‐based) [7].
2.4. Magnetic NPs
Last but not least is the use of supermagnetic iron oxide nanoparticles (SPIOs), which are used for
magnetic separation in several immunomagnetic applications such as cell sorting, nucleic acid
extraction, purification, and detection of pathogens, cancer cells, and generally rare popula‐
tions in a solution/sample [8].
2.5. Carbon nanotubes or nanopores (CNTs–CNPs)
There are a variety of challenges associated with the flow of liquids through carbon nano‐
tubes and nanopores. These are small electrically insulated tubes or pores which can detect a
single molecule when this passes through the tube or pore. The molecule's detection is based
on the change of the ionic current of the electrolyte solution containing the molecules of
interest, which results in a change of the electrical current (translocation event signal) [7]. The
incorporation of biochips and nanofluidics with nanopores or nanotubes will be able to replace
the existing sequencing approaches of DNA in the clinical practice, as each DNA base has
unique molecular structure and thus a unique translocation event signal. To this aim,
nanofluidic devices are developed that employ multiple measurements on single molecules
to enhance the ability to size DNA molecules. Techniques to integrate membranes contain
nanopores into microfluidic devices, which decrease noise and enable the design of net‐
works containing nanopores.
2.6. Silicon nanowires (SiNWs)
Nanowires are currently believed to be unique and advantageous for the construction of a
nanobiosensing device. Nanowires are nanoscale channels through which current is passed
and can be constructed from carbon nanotubes, metal oxides or silicon, and they require high
temperatures to be synthesized and are usually prepared on silicon wafers. Antibodies are
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usually used as detectors in the surface of the nanowire. Antibodies interact with the biolog‐
ical target of interest, and the conformational change results in a change in the current that
passes through the nanowire, allowing a sensitive and specific detection. The use of nano‐
wires in an array mode, where different antibodies are conjugated to each nanowire, allows
the mass detection of different types of disease or the creation of a personalized molecular
profile in one type of disease [7].
2.7. Graphene, metal films and nanostructured surfaces
Graphene, metal films, and nanostructured surfaces are all in the class of 2D nanostructures
which are structures with one dimension of ∼100 nm in size. Their incorporation in nano‐
diagnostic is their use as racks in order to conjugate and immobilize ligands for targeted
binding when the sample comes across them. They usually are sheets of a certain nanomate‐
rial, which have special properties different from that of the corresponding bulk material. For
example, metal films exhibit the same advantages with metal NPs, for example, the SPR effect,
and thus, they are used in the construction of label‐free SPR biosensors. As for nanostruc‐
tured surfaces, they are in reality electrodes with their surface linked with nanotubes or
nanoparticles. Finally, graphene will offer great sensitivity in rapid diagnostic tests, since it is
an incredibly stable one‐layer 2D surface of carbon atoms with unique optical and conduc‐
tive properties [7].
3. Nanotechnology‐on‐a‐chip or nanofluidics
A nanobiochip is comprised of integrated biomolecules or biologically active artificial
structures which are usually smaller than that of cell's. The chip contains microarrays, which
are minitest sites, on a solid surface, and this allows for multiple tests to be carried out
simultaneously. Therefore, identification of a specific molecular signature, which will be
unique to the diagnosis, can be done through thousands of biochemical reactions being
performed on the nanobiochip [9, 10].
The identification and quantification of a variety of molecules will be permitted through the
combination of nanotechnologies, such as nanofluids and nanobiosensors, with biochips, and
this will lead to the generation of future in vitro diagnostic chip‐based devices. Nanofluidic
structures have small fluidic conducts which means they are automatically applied in
situations where you have extremely small quantities of the sample. This includes Coulter
counting, analytical separations and determinations of biomolecules, such as proteins and
DNA and facile handling of mass‐limited samples. Lab‐on‐a‐chip structures comprise one of
the more promising tools of nanofluidics. The advance and production of lab‐on‐chip devices
for PCR and other related techniques mean that nanofluidics have had a substantial impact in
biotechnology, medicine, and clinical diagnostics. In nanofluidics, a chamber of up to a few
hundred nanometers in size contains a liquid sample which is then manipulated and ana‐
lyzed. As the volume of the samples are so small, this allows for a substantial reduction in the
amount of sample needed for the analysis as well as allowing for the advantages of laminar
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flow conditions, high surface to volume rations, low concentrations, molecular confinement,
and low heat capacity to be used. On the other hand, nanofluidics also generates new
challenges in the device design and manufacture, the accurate control of flow and mixing, and
the sensitivity of molecular detection, and they are starting to be used in many diagnostic and
analytical devices [10, 11].
An in vitro simple detection system can therefore be established, which allows hundreds of
cantilever biosensors to be used simultaneously on the same array. A lab‐on‐a‐chip device
could be produced through additional advances of this technique which include the com‐
plete integration with fluidic handling system, other analytical techniques and signal extrac‐
tion electronic. The initial proposition, by Berger et al., was for a “laboratory‐on‐a‐tip” which
described the potential combination of cantilever sensors with atomic force microscopy (AFM).
In this proposed technique, a cantilever with a tip could examine and detect with nanometer
resolution where the biochemical analysis is executed. Thus, in conclusion, an alternative PCR
which has the potential to replace microarray detection techniques is offered through
cantilever nanobiosensing for the identification of SNPs, oncogenes, viruses, bacteria, and a
variety of other pathogens. Additionally, the most common in vitro application of SPR
biosensor chip devices is defining the affinity parameters of biomolecular interactions, where
a sensorgram is used to report the association and dissociation of the ligand and its binding
partner, which is added once the ligand has been immobilized on the sensor chip. There are
numerous advantages of using this technique in comparison with conventional methods for
affinity measurement, and these include little material being required, it is very quick, and
finally, no tracer is needed for labeling. The expanding field of proteomics has seen the most
recent developments in SPR where it is combined with matrix‐assisted laser desorption/
ionization time of flight mass spectrometry (MALDI‐TOF), and this permits the study of
biomolecular interactions between molecules of which at least one is known. The interacting
molecule cannot always be identified when a variety of proteins is used within the interac‐
tion study. However, using the MALDI‐TOF technique allows you to determine the mole‐
cule that interacts with the sensor from the mixture [10, 11].
4. Applications of nanotechnology in in vitro nanodiagnostics
Up to now, nanostructures are successfully incorporated to in vitro diagnostics for the
construction of nanobiosensors and in vitro rapid diagnostic tests mainly in order to im‐
prove existing tests and make them more effective or create innovative diagnostic test
approaches that will be able to be incorporated in point‐of‐care applications of every day
clinical practice. Nanodiagnostic applications are currently focused on two main approaches,
such as the use of nanoparticles as biomarkers and the development of novel nanosensors that
incorporate various nanostructures, such as carbon nanotubes, lateral nanostructures or
nanothin surface layers via labeled nanosensors or label‐free nanosensors. With the use of in
vitro diagnostic tests based on nanotechnology, various clinical and research fields will be
improved such as genotyping techniques, immunohistochemistry assays, detection of
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biomarkers, early cancer detection, and others. Below, we are going to describe some of these
applications.
4.1. Nanosensors for glucose monitoring
The management of diabetes disease, besides the great progress in the maintenance of insulin,
is still intriguing. In the current clinical practice, diabetes patients need to tolerate tandem
blood samples in order to monitor blood glucose and therefore minimize the possibility of
hyper‐ or hypoglycemia, together with the aftermaths. Thus, it is still now an essential task to
design a management approach for the monitoring of blood glucose that is non‐invasive, fast,
and sensitive. The use of nanotechnology for the fabrication of a rapid and portable diagnos‐
tic test offers the aforementioned advantages. However, it is difficult task to design the ideal
test, since the ideal biosensor has to be small, low‐cost, with simple function, accurate in the
measurement and of course portable. Furthermore, this future test will have to minimize the
blood volume needed for the test and the possible contaminations and to assure the accura‐
cy of the measurement. Even further, an implantable microfluidics biosensor could provide a
more accurate management of in vivo glucose monitoring and insulin administration. Barone
et al. [12] used solution‐phase optical single‐walled CNTs (SWCNTs) sensors which have a
tunable near‐infrared (NIR) emission that responds to changes in the local dielectric func‐
tion, but remains stable to permanent photobleaching. SWCNTs are integrated with beta‐D‐
glucose sensing as a model system; for example, they are conjugated with glucose oxidase, an
enzyme that degrades glucose molecules and ferricyanide a molecule that takes electrons from
the NTs, quenching their capacity to glow under NIR. In order to test the in vivo capacity of
the nanosensors, they implanted them in situ in a human skin tissue sample and excited with
NIR. The results demonstrated that the higher the glucose concentration, the greater the
fluorescence. Thus, the nanosensors were found able to modulate their emission in response
to the adsorption of specific biomolecules, suggesting that nanoparticle optical sensors are an
attractive solution for glucose monitoring [12]. However, such techniques that use glucose
consumption turned out to have many disadvantages regarding the continuous glucose
monitoring. Therefore, technique based on competitive affinity binding of glucose and
subcutaneously implanted enzymatic electrochemical detection is being recently a very
attractive approach, since they can be highly stable and low drift. For example, the use of a
polysaccharide solution such as dextran conjugated to a glucose‐binding protein such as
concanavalin A (Con A), which competitively binds glucose leading to reversible de‐cross
linking of the dextran–Con A complex. In the unbound state, the changes in the fluorescence
or viscosity of the solution can be detected. Alternatively, synthetic glucose‐responsive
polymers have been recently fabricated from various research groups in order to substitute
Con A, which is found to be cytotoxic and fast degradable. Huang et al. [13] fabricated a
biocompatible, glucose‐specific polymer (PAA‐ran‐PAAPBA) in order to create a sensor based
on the sensing principle of the viscosity detection changes due to affinity binding between
glucose and (PAA‐ran‐PAAPBA). Microelectromechanical system (MEMS) technology was
incorporated for the fabrication of the sensor device that allowed long‐term continuous glucose
monitoring [14]. The device uses a magnetically responsive vibrating Parylene polymer
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microcantilever as sensing element, situated in a microchamber, which was filled by PAA‐ran‐
PAAPBA. Glucose passes through the membrane and binds reversibly to (PAA‐ran‐PAAP‐
BA) polymer, causing a viscosity alteration in the solution. The MEMS device was suggested
as a subcutaneously implanted sensor for stable and reliable continuous monitoring of glucose
in practical diabetes management [13].
Recently, a type of miniaturized sensors called optodes has attracted the scientists’ attention.
Nano‐optodes consist of a chemical that responds to an analyte, a polymer to immobilize the
chemical transducer and instrumentation (optical fiber, light source, detector, and other
electronics) [15]. They can be integrated with several optical measurement schemes such as
reflection, absorption, evanescent wave, luminescence (fluorescence and phosphorescences)
that is the most popular methodology, chemiluminescence and surface plasmon resonance.
Balaconis et al. [16] used nanofiber fluorescent nano‐optodes in order to measure the dynam‐
ic changes of glucose concentrations based on the competitive binding between a hydropho‐
bic boronic acid recognition molecule, a chromophore and glucose. The concentration change
of glucose in the membrane was monitored by measuring the change of the optical signal.
Nano‐optodes are proven to be functional both in vitro and in vivo and to be very sensitive,
since they can detect even small molecules [15, 16].
4.2. Detection of bacteria and viruses
Nowadays, pathogen detection is performed using very sensitive techniques such as ELISA,
PCR, and sequencing techniques. However, the aforementioned techniques are considered
very expensive; they require excessive sample preparation and have long validation times
with no early response; and they need expertise personnel to perform the test. Therefore, the
advantageous optical, magnetic, electrical, and catalytic characteristics of nanomaterials can
offer faster, more sensitive, specific, and cheaper diagnostic assays that no experts will be
needed for their use, in order to detect microbial pathogenesis. Pathogens express on their
membranes various molecules such as glyco‐, lipoproteins, glycopeptides, carbohydrates,
and lipids. Thus, nanotechnology usually uses antibodies as targeting ligands for the
development of various immunoassays. For example, gold and silver NPs have been broadly
used for conjugation with affinity ligands, finding attractive applications as chemical sensors
or even further for the generation of nanoscale arrays of pathogen‐targeting ligands.
Moreover, NPs can also be conjugated with specific oligonucleotides sequences that bind
pathogen nucleic acid sequences to generate colorimetric changes. Other nanoparticles
including fluorescent QDs and CNTs have been used in various applications including DNA
detection and the development of immunoassays for the detection of bacteria and viruses.
Besides NPs based‐assays, miniaturized microfluidic system or lab‐on‐a‐chip (LOC) is a
futuristic and attractive field of research for accurate and point of care management of
microbial infections.
Very recently, Wu et al. [17] fabricated a Microbead Quantum‐dots Detection System (MQDS)
in order to identify and measure target DNAs of pathogenic microorganisms and substi‐
tute PCR amplifications. All reporter probes and internal control probes were conjugated
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with quantum dots that fluoresce at different emission wavelengths using the click reac‐
tion, in order to monitor the binding process by flow cytometry [17]. Zhang et al. [18] created
an innovative microfluidic microbead array with QDs tags for HBV genotyping. This method
detected in vitro‐transcribed RNA in serum samples with increased sensitivity of 1000 copies/
mL of HBV virus. Thus, they were able to create a QDs‐based biochip of high specificity and
sensitivity for virus genotyping based on DNA hybridization. This microfluidic device
managed to incorporate the microarray technology with the advantages of QDs when used
as fluorescent agents and thus suggested a microfluidic approach for the highly sensitive
detection of virus DNA of analysis with the use of small sample amount and fast detection
time [18]. Moreover, Fu et al. [19] used Raman reporter‐labeled AuNPs as SERS nanotags
which target the HIV‐1 DNA marker. The oligonucleotide‐conjugated AuNPs were anch‐
ored in user‐friendly lateral flow (LF) strips that have been extensively used for point‐of‐care
(POC) self‐diagnostics. They managed to analyze HIV‐1 DNA with high sensitivity by
monitoring the characteristic of Raman peak intensity of the DNA‐conjugated AuNPs. The
detection limit of these SERS‐based lateral flows was observed to be at least 1000 times more
sensitive compared to colorimetric or fluorescent detection methods. These results demon‐
strate the potential feasibility of the proposed SERS‐based lateral flow assay to quantitative‐
ly detect a wide range of genetic diseases with high sensitivity [19]. Tsang et al. [20] used
upconversion nanoparticles (UNPs), based on the upconversion phenomenon where the
absorption of photons results in a shorter wavelength emission of light compared to the
excitation wavelength. So far, the most common UNPs are the lanthanide Yb3+ to Er3+ ions as
used in this study, where Yb3+ ions have the ability to convert to Er3+ ions under NIR light
and emit at green, visible wavelengths. These UNPs are linked with AuNPs which are
conjugated with oligonucleotide probes (AuNPs) targeting Ebola virus oligonucleotide, and
this nanocomposite is anchored on a nanoporous alumina (NAAO) membrane. Taking into
consideration that Ebola outbreaks are currently of great concern, it is essential to investi‐
gate the feasibility of detection nanodevices of into low‐cost, rapid, and with ultrasensitive
detection of various pathogens, especially epidemic viruses [20].
Besides DNA, antimicrobial peptides (AMPs) are promising affinity agents for the develop‐
ment of biosensors due to the possibility of recognizing a various pathogenic biomarkers
(bacteria, fungi, toxins, viruses), in order to design biosensors that exhibit more specificity and
sensitivity regarding the detection limits. In the bound state, the biosensor can be evaluated
via electrochemical impedance and fluorescence spectroscopies. Mannoor et al. [21] fabricat‐
ed an array electrobiosensor functionalized with the AMP magainin I on the surface of AuNPs,
in order to detect pathogenic bacteria. When the specific reaction occurs between magainin I
and the sample, dielectric alterations of the surface's properties are detected, a change that
allows the selective detection of pathogenic Gram‐negative bacteria E. coli and Salmonella
typhimurium related to the non‐pathogenic E. coli and the Gram‐positive species Listeria
monocytogenes [21]. It is also possible to use synthetic peptides in order to maximize the
selectivity like Lillehoj et al. [22] who designed a microelectromechanical sensor using two
synthetic peptides (C16G2cys and G10KHc) for the detection of Streptococcus mutans and
Pseudomonas aeruginosa. On the other hand, Cho and Irudayaraj [23], proposed an in situ
immuno‐AuNP network‐based ELISA biosensor to detect pathogens with high sensitivity. The
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in situ ELISA biosensor was able to detect E. coli and S. typhimurium in real sample condi‐
tions within 2 h of inoculation pathogens at extremely low concentrations.
As already mentioned, 2D nanostructures can offer great sensitivity in rapid diagnostic tests.
Mevold et al. [24] used graphene–PDDA nanosheets absorbed with AuNPs. PDDA is a
homopolymer for the dispersibility of graphene, since it charges positively the graphene and
protects the solution from the aggregation of graphene. The positive charge of AuNPs/
graphene–PDDA nanosheets serves to easily capture the negative charge of Staphylococcus
aureus and small molecules (adenine) for SERS rapid detection [24]. Moreover, Li et al. [25]
aimed to detect foodborne pathogens, such as Escherichia coli O157:H7, Salmonella enterica,
Vibrio cholera, and Campylobacter jejuni, all at the same time using multiplex PCR and magnet‐
ic nanoparticle probes (MNPs). The MNPs were conjugated with streptavidin, immobilized in
an oligonucleotide array and used in order to visualize the hybridization between the
oligonucleotide array and the 5’ biotinylated single‐strand PCR products. Interestingly, the
signal could be easily detected by naked eye or a microscope. The streptavidin–MNPs
microarray detected 316 foodborne pathogens/mL and thus suggested as a sensitive, specific,
and easy‐to‐use tool for the fast detection of foodborne pathogens in a modestly equipped
laboratory, being an attractive approach for future rapid diagnostic tests [25].
4.3. Nanotechnology in cancer diagnosis
The incorporation of nanotechnology in cancer diagnosis is essential, since early detection of
the disease can improve the chances of treatment. In addition, the reduction of the needed time
for the nanotest will lead in more precise decision‐making in every day clinical practice and
treatment costs.
Up to now, several nanomaterials, such as AuNPs, semiconductor II–VI QDs, silicon nano‐
wires (SNWs), carbon CNTs, and graphene, have been used in order to detect various cancer
markers (proteins/peptides or DNA/RNA) in a sensitive and specific manner, especially when
used for the construction of high‐performance nanobiosensors. For instance, FET‐SNWs have
been used for the detection of several prostate cancer biomarkers, such as prostate‐specific
antigen (PSA) at the level of fg/ml of PSA for monitoring prostate cancer and predicting the
risk of early biochemical relapse and the prostate biomarker 8‐hydroxydeoxyguanosine (8‐
OHdG) by using a SNWs functionalized with antibodies against 8‐OHdG [26]. PSA, prostate‐
specific membrane antigen, platelet factor‐4, and interleukin‐6 prostate cancer biomarkers
have also been detected by electrochemical NTs [27, 28].
Furthermore, using a nanowire technology (nCounter Analysis System), ribonucleic acid
(RNA) expression levels of cancer‐testis antigens (CTAs) have been measured, as biomark‐
ers for aggressive prostate cancer. This nanowire technology offers the possibility of a sensor
chip, is able to simultaneously detect more than one of cancer marker, and measures a panel
of biomarkers related to a specific cancer type and/or individual, thus contributing to the
personalization of cancer diagnosis [29]. Lee et al. [30] developed a nanowire substrate‐enabled
laser‐scanning imaging combined with flow cytometry for the isolation and quantitation of
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circulating tumor cells from a human lung carcinoma sample mixture of tumor cells and
leukocytes.
Interestingly, CNTs and SNWs have been utilized for detection of various volatile organic
compounds (VOCs) in breath samples of lung and gastric cancer patients, respectively [31].
Thus, Tran et al. [32] constructed a portable read‐out NWs on‐a‐chip device, by the addition
of a complementary metal‐oxide semiconductor (CMOS) on FET‐SiNWs, creating a nanoplat‐
form that could detect ALCAM in serum at a detection limit of 15.5 pg/ml, in <30 min. Besides
cancer biomarker detection, FET‐SiNWs and zinc oxide nanowires (ZnONWs) have been used
to detect ssDNA and mi‐RNAs related to the initiation and progression of various cancer
types [33].
Just like other nanobiosensors, nanocantilevers were demonstrated to be able to detect
PSA at low levels (0.2 ng/ml–60 μg/ml) for the detection of prostate cancer. Huber et al.
[34] used microcantilever arrays to detect BRAFV600E mutation nanomechanically without
amplification, from total RNA samples isolated from malignant melanoma cells. Wang et
al. [35] fabricated a new cantilever array‐based biosensor based on MEMS for the detection
of alpha‐fetoprotein (AFP), a liver cancer biomarker, with high accuracy, while Liu et al.
[36] detected the same biomarker for hepatocellular carcinoma at the level of ng/ml, using
a resonant microcantilever electromagnetic resonance‐exciting and piezoresistive read‐out
elements on‐chip integrated, in order to measure frequency‐shift versus specific‐adsor‐
bed mass.
So far, nanostructures such as QDs, AuNPs, and superparamagnetic NPs have been the most
successfully incorporated in in vitro diagnostic applications, due to their potential to be
functionalized by several biomolecules (antibodies, oligonucleotides) against the target
biomolecules of interest. In the field of in vitro diagnostics, nanoparticles are mainly used as
markers for biomolecules. On the other hand, conventional fluorescent dyes already used in
medical laboratory tests, in PCR assays, and in biochips are not photostable or suitable for
multiplexing. Jokerst et al. [37] used semiconductor nanoparticle QDs combined with a
microfluidic biosensor for the multiplex quantitation of cancer biomarkers such as carcinoem‐
bryonic antigen (CEA), cancer antigen 125 (CA125), and Her‐2/Neu (C‐erbB‐2) in serum and
whole saliva specimens. This QD nanobiochip assay system resulted in a 30 times signal
amplification, compared with standard molecular fluorophores [37]. Moreover, supermag‐
netic iron oxide nanoparticles are used, integrated with applications such as cell sorting,
nucleic acid extraction and purification for the detection and isolation of circulating tumor
cells of several types of cancer such as colorectal, lung, and breast cancer [38–40]. Besides
circulating tumor cells, recently circulating extracellular vesicles and exosomes are demon‐
strated to serve as cancer biomarkers. Kanwar et al. [41] fabricated a microfluidic device
(ExoChip) in polydimethylsiloxane (PDMS) and conjugated with antibodies against CD63,
overexpressed mainly in exosomes. The ExoChip was able to measure fluorescent‐carbocya‐
nine‐dyed exosomes from pancreatic cancer patients, compared to those from healthy subjects.
Overall, the aim of this study was to suggest a novel approach for cancer molecular profil‐
ing that can be applied in various cancer types. Specifically, they managed to create an
Nanotechnology‐Based Rapid Diagnostic Tests
http://dx.doi.org/10.5772/63908
99
exosomal‐microRNA profiling that could enable the future molecular screening and diagno‐
sis of human cancers [41].
5. Discussion and future perspectives
Up to now, the incorporation of nanostructures in medicine is offering the development of
diagnostic tools of high sensitivity, advantageous contrast agents compared to traditional dyes
already in use, novel personalized treatment approaches, and drug delivery vehicles. Taking
into consideration small‐sized sample volumes, fast reaction times, specificity and sensitivi‐
ty of nanosystems, in the near future they will be able to bring mobile testing devices into every
day clinical practice. Regarding in vitro nanodiagnostics, nanotechnology allows the construc‐
tion of high sensitive nanosensors and in vitro tests to develop new diagnostic nanoplat‐
forms and to allow point of care applications. Many of the technologies described in this
chapter are demonstrated to be versatile; for instance, they are suitable for DNA and protein
detection, and they detect very few pathogens, such as bacteria and viruses, or molecules such
as low concentration of glucose that would not be detected with conventional techniques. The
incorporation of nanotechnology in medicine will lead to the development of rapid diagnos‐
tic tests, which will result in the improvement of clinical decision‐making and treatment costs.
For example, rapid diagnostic nanotests offer early detection of disease such as cancer
improving this way the possibilities of treatment.
NPs are the most versatile material for developing diagnostics, since they can be conjugated
with various agents and serve as tags or labels. Thus far, there are several efforts in the way
in order to develop nanoparticle‐based systems for disease detection. Nanosphere, Inc. has
launched the Verigene system which uses AuNPs. Verigene system is a molecular diagnos‐
tic system for rapid diagnostic evaluation that enables rapid treatment decisions regarding
targeted therapy for various infections in bloodstream, respiratory tract, and gastrointestinal
tract. The technology can also be applied in the future for other life‐threatening diseases such
as cardiovascular, autoimmune diseases, and cancer. T2 Biosystems developed T2MR, a
diagnostic detection method that uses miniaturized magnetic resonance technology in order
to measure how water molecules react under magnetic fields. The T2MR technology plat‐
form offers a fast, simple, and sensitive alternative to existing diagnostic methodologies and
uses magnetic nanoparticles to identify proteins, nucleic acids, and other materials. T2MR
technology enables low limit of detection, as low as 1 cell/mL, compared to the 100–1000 cell/
mL required by PCR‐based in vitro diagnostics. Up to now, T2Candida is in clinical trials and
can identify the five clinically relevant species of Candida with 99.4% specificity and 91.1%
sensitivity, directly from whole blood which enables physicians to initiate appropriate therapy
on the same day. All other FDA‐cleared Candida diagnostics require a blood culture to
determine the Candida species, which takes up to 6 days for species identification or nega‐
tive result. On the other hand, the conjugation of virus‐specific antibodies in AuNPs can enable
the rapid diagnosis of flu virus. The AuNPs–antibodies complex targets the virus in a way that
larger AuNPs‐virus aggregates are formed. Subsequently, in the presence of light, the sample
leads to an increase of the reflected light due to these aggregates, allowing a much faster
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validation and virus detection than with the tests currently used. The same notion of the
formation of aggregates around the biomolecule of interest is used for the fast and specific
detection of various diseases.
Currently, QD technology is the most broadly employed nanotechnology for diagnostic
developments, especially for cancer management. The only concern about QDs is the in vivo
toxicity. However, researchers suggest the use of QDs composed of silicon, which is be‐
lieved to be less toxic than the cadmium contained in many QDs.
Regarding circulating cancer cell detection, researches have recently published the
NanoFlare genetic‐based technology that enables the detection of living circulating tumor
cells in bloodstream. A NanoFlare is designed to enter cells and to hybridize with cancer‐
specific oligonucleotide sequences. NanoFlare has a great advantage, such as all
nanoparticles due to their size: the fact that they can enter inside the cell gives the
opportunity of the use of various biomolecules that are present inside the cell and not
only markers anchored on the cell's surface. So when NanoFlare attaches to the cancer‐
specific target into the cell,  a reporter “flare” is released that produces a detectable
fluorescent signal.
Nanosensors and blood sensors capable of detecting multiple pathogens or chemical com‐
pounds are one such example. Point‐of‐care diagnostics are possible with nanosensors and
also an attractive technology towards point‐of‐care diagnosis that will be easy for the patient
to use at home and will enable the integration of diagnostics with therapeutics and the
development of personalized treatment approaches. Blood sensors, especially cantilevers
arrays, are characterized by important advantages since the technology of nanomechanical
detection requires no labels and/or external probes, and optical excitation and is rapid, highly
specific, sensitive, and portable. The above give the opportunity to detect pathogens or
molecules in blood samples and are a great example of future point‐of‐care diagnostic tools.
Furthermore, the upper goal regarding the construction of diagnostic biochips will be the
miniaturization of the biosensor chips to range of “nano”‐dimensions. Thus, the use of
nanotechnology in rapid diagnostic tests will lead to devices with nanodimensions, sensitive,
easy to use, and non‐expensive in order to allow direct signal observation, manipulation,
analysis, and result validation of a single biological molecule from a single cell. This offers new
opportunities and provides powerful tools in the fields of genomics, proteomics, molecular
diagnostics, and high‐throughput screening.
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